Medication Guide App

Pegaspargase Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Acute Lymphoblastic Leukemia

2,500 international units/m2 IM or IV no more frequently than every 14 days

Use: Component of a multi-agent chemotherapeutic regimen for treatment of patients with first line acute lymphoblastic leukemia, acute lymphoblastic leukemia and hypersensitivity to asparaginase.

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

1 year or older: 2,500 international units/m2 IM or IV no more frequently than every 14 days.

Use: Component of a multi-agent chemotherapeutic regimen for treatment of patients with: first line acute lymphoblastic leukemia, acute lymphoblastic leukemia and hypersensitivity to asparaginase.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 1 year.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-IM: Single injection site volume administered should be limited to 2 mL. If volume to be administered is greater than 2 mL, multiple injection sites should be used. Use only one dose per vial and discard unused product.
-IV: Pegaspargase should be given over a period of 1 to 2 hours in 100 mL of sodium chloride or dextrose injection 5%, through an infusion that is already running. After the solution is diluted for IV use, the solution should be used immediately.
-Do not administer if drug has been frozen, stored at room temperature 15C to 25C (59F to 77F) for more than 48 hours, shaken or vigorously agitated.

Storage requirements:
-IV: If immediate use is not possible, the diluted solution should be stored at 2C to 8C (36F to 46F). Storage after dilution should not exceed 48 hours from the time of preparation to completion of administration.
-Protect infusion bags from direct sunlight.
-Parenteral drug products should be inspected for particulate matter, cloudiness, or discoloration prior to administration. If any of these are present, discard the vial or container.

Hide
(web4)